Hollencrest Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Hollencrest Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$6	–	1191
2024 Q2	$6	Hold	1	–	–	﹤0.01%	1079
2024 Q1	$51	Hold	1	–	–	﹤0.01%	1063
2023 Q4	$120	Hold	1	–	–	﹤0.01%	1015
2023 Q3	$478	Hold	1	–	–	﹤0.01%	1005
2023 Q2	$3.11K	Hold	1	–	–	﹤0.01%	916
2023 Q1	$1.8K	Hold	1	–	–	﹤0.01%	975
2022 Q4	$1.76K	Buy	+1	New	+$3.49K	﹤0.01%	962
2021 Q4	–	Sell	-6	Closed	-$54K	–	412
2021 Q3	$54K	Hold	6	–	–	﹤0.01%	372
2021 Q2	$63K	Hold	6	–	–	0.01%	373
2021 Q1	$115K	Buy	+6	New	+$70K	0.01%	347

Other funds holding SEEL

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CHA

Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Hollencrest Capital Management's SEEL Position: Q3 2024 in Review

Hollencrest Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2024, closing a stake of 1 share — an estimated $6 sold.

Hollencrest Capital Management first reported a position in SEEL in Q1 2021 and held it in 10 quarters. The position peaked at $115K in Q1 2021. 15 funds tracked by Wall St. Rank hold SEEL as of Q3 2024.

Hollencrest Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Hollencrest Capital Management sold 1 Seelos Therapeutics, Inc. Common Stock share in Q3 2024, an estimated $6.
Hollencrest Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Hollencrest Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $115K in Q1 2021.
15 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Hollencrest Capital Management's 13F filing for Q3 2024, filed 1 Nov 2024.